BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32460379)

  • 1. Intestinal P-gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications.
    Zamek-Gliszczynski MJ; Patel M; Yang X; Lutz JD; Chu X; Brouwer KLR; Lai Y; Lee CA; Neuhoff S; Paine MF; Sugiyama Y; Taskar KS; Galetin A
    Clin Pharmacol Ther; 2021 Jan; 109(1):55-64. PubMed ID: 32460379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
    Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
    Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.
    Taskar KS; Yang X; Neuhoff S; Patel M; Yoshida K; Paine MF; Brouwer KLR; Chu X; Sugiyama Y; Cook J; Polli JW; Hanna I; Lai Y; Zamek-Gliszczynski M;
    Clin Pharmacol Ther; 2022 Sep; 112(3):573-592. PubMed ID: 35612761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Determinants of Daprodustat Drug-Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B-CYP2C8 Interplay.
    Bi YA; Jordan S; King-Ahmad A; West MA; Varma MVS
    Clin Pharmacol Ther; 2024 Jun; 115(6):1336-1345. PubMed ID: 38404228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
    Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
    J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
    Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.
    Elmeliegy M; Vourvahis M; Guo C; Wang DD
    Clin Pharmacokinet; 2020 Jun; 59(6):699-714. PubMed ID: 32052379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
    Tatosian DA; Yee KL; Zhang Z; Mostoller K; Paul E; Sutradhar S; Larson P; Chhibber A; Wen J; Wang YJ; Lassman M; Latham AH; Pang J; Crumley T; Gillespie A; Marricco NC; Marenco T; Murphy M; Lasseter KC; Marbury TC; Tweedie D; Chu X; Evers R; Stoch SA
    Clin Pharmacol Ther; 2021 Feb; 109(2):403-415. PubMed ID: 32705692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
    Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
    Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
    Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
    J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
    Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic account of distinct change in organic anion transporting polypeptide 1B (OATP1B) substrate pharmacokinetics during OATP1B-mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
    Hegde PV; Morse BL
    Drug Metab Dispos; 2024 May; ():. PubMed ID: 38740464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
    Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
    Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
    Kikuchi R; Chothe PP; Chu X; Huth F; Ishida K; Ishiguro N; Jiang R; Shen H; Stahl SH; Varma MVS; Willemin ME; Morse BL
    Clin Pharmacol Ther; 2023 Dec; 114(6):1170-1183. PubMed ID: 37750401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo.
    Niu C; Wang Y; Zhao X; Tep S; Murakami E; Subramanian R; Smith B; Lai Y
    Drug Metab Dispos; 2019 Dec; 47(12):1433-1442. PubMed ID: 31582395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
    Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
    Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.